◎ Sugi Atlas

Atlas / Drug / Upadacitinib

Upadacitinib

drug
On this page

Also known as ABT-494Upadacitinib anhydrousUpadacitinib component of abbv-599UPADACITINIB TARTRATEUpadactinib

Summary

Upadacitinib (CHEMBL3622821) is an approved small molecule (ATC L04AF03) targeting JAK1, JAK2, and JAK3; indicated across 13 conditions including atopic eczema and crohn disease.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L04AF03
  • Targets: 4 (JAK1, JAK2, JAK3…)
  • Indications: 13 conditions
  • Clinical trials: 101
  • Chemistry: 380.4 Da · C17H19F3N6O

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL3622821
NameUpadacitinib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID58557659
ATCL04AF03
Molecular formulaC17H19F3N6O
Molecular weight380.4
InChIKeyWYQFJHHDOKWSHR-MNOVXSKESA-N

SMILES: CC[C@@H]1CN(C[C@@H]1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F

IUPAC name: (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

Also known as: ABT-494, Upadacitinib, Upadacitinib anhydrous, Upadacitinib component of abbv-599, UPADACITINIB, UPADACITINIB TARTRATE, Upadactinib

Parent form; salt/anhydrous children: CHEMBL3707269, CHEMBL5315119

Patent coverage: 1,081 distinct patent families (2,726 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
JAK1Janus kinase 1Inhibition7.372.8%P23458
JAK2Janus kinase 2Inhibition6.920.7%O60674
JAK3Janus kinase 3Inhibition5.640.6%P52333
TYK2tyrosine kinase 2Inhibition5.330.8%P29597

Broader ChEMBL bioactivity targets: 31 (assay-derived). Sample: Tyrosine-protein kinase JAK2, Proto-oncogene tyrosine-protein kinase receptor Ret, Tyrosine-protein kinase JAK3, Aurora kinase B, Non-receptor tyrosine-protein kinase TYK2, Ribosomal protein S6 kinase alpha-3, Janus Kinase (JAK), Tyrosine-protein kinase Lck, Vascular endothelial growth factor receptor 2, Tyrosine-protein kinase JAK1.

Bioactivity

ChEMBL activities: 156 potent at pChembl ≥ 5 of 156 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
JAK19.1IC500.8nMCHEMBL_ACT_25452148
JAK19.05Ki0.89nMCHEMBL_ACT_22391386
JAK18.8IC501.6nMCHEMBL_ACT_25754505
JAK28.8IC501.6nMCHEMBL_ACT_25754517
JAK38.8IC501.6nMCHEMBL_ACT_25754528
JAK18.8IC501.6nMCHEMBL_ACT_26316413
JAK18.7IC502nMCHEMBL_ACT_25754510
JAK28.7IC502nMCHEMBL_ACT_25754522
JAK38.7IC502nMCHEMBL_ACT_25754533
JAK18.7IC502nMCHEMBL_ACT_26316418
JAK18.52IC503nMCHEMBL_ACT_25754512
JAK28.52IC503nMCHEMBL_ACT_25754524
JAK38.52IC503nMCHEMBL_ACT_25754535
JAK28.52IC503nMCHEMBL_ACT_26316420
JAK28.51IC503.1nMCHEMBL_ACT_25452160
JAK18.4IC504nMCHEMBL_ACT_25754511
JAK28.4IC504nMCHEMBL_ACT_25754523
JAK38.4IC504nMCHEMBL_ACT_25754534
JAK18.4IC504nMCHEMBL_ACT_26316419
JAK18.3IC505nMCHEMBL_ACT_28292177
JAK18.1IC508nMCHEMBL_ACT_18722778
JAK28.1IC508nMCHEMBL_ACT_18863604
JAK18.1IC508nMCHEMBL_ACT_18991847
JAK28.1IC508nMCHEMBL_ACT_25785202
JAK28.1IC508nMCHEMBL_ACT_26316317
JAK18IC5010nMCHEMBL_ACT_25754507
JAK28IC5010nMCHEMBL_ACT_25754519
JAK38IC5010nMCHEMBL_ACT_25754530
JAK18IC5010nMCHEMBL_ACT_26316415
JAK17.96IC5011nMCHEMBL_ACT_25754501

Target pathways

Aggregated over 4 target gene(s): JAK1, JAK2, JAK3, TYK2.

Top Reactome pathways

86 total, by targets touching each:

PathwayTargetsGenes
Interleukin-4 and Interleukin-13 signaling4JAK1, JAK2, JAK3, TYK2
Interleukin-20 family signaling4JAK1, JAK2, JAK3, TYK2
Potential therapeutics for SARS4JAK1, JAK2, JAK3, TYK2
Interleukin-6 signaling3JAK1, JAK2, TYK2
MAPK3 (ERK1) activation3JAK1, JAK2, TYK2
MAPK1 (ERK2) activation3JAK1, JAK2, TYK2
Cytokine Signaling in Immune system3JAK1, JAK2, JAK3
Signal Transduction3JAK1, JAK2, JAK3
Disease3JAK1, JAK2, JAK3
Immune System3JAK1, JAK2, JAK3
Signaling by Interleukins3JAK1, JAK2, JAK3
Interleukin-2 family signaling3JAK1, JAK2, JAK3
Interleukin-3, Interleukin-5 and GM-CSF signaling3JAK1, JAK2, JAK3
Infectious disease3JAK1, JAK2, JAK3
RAF/MAP kinase cascade3JAK1, JAK2, JAK3
MAPK family signaling cascades3JAK1, JAK2, JAK3
MAPK1/MAPK3 signaling3JAK1, JAK2, JAK3
IL-6-type cytokine receptor ligand interactions3JAK1, JAK2, TYK2
Interleukin-35 Signalling3JAK1, JAK2, TYK2
Interleukin-12 signaling3JAK1, JAK2, TYK2
Interleukin-27 signaling3JAK1, JAK2, TYK2
Interleukin receptor SHC signaling3JAK1, JAK2, JAK3
Signaling by CSF3 (G-CSF)3JAK1, JAK2, TYK2
SARS-CoV Infections3JAK1, JAK2, JAK3
Inactivation of CSF3 (G-CSF) signaling3JAK1, JAK2, TYK2
Viral Infection Pathways3JAK1, JAK2, JAK3
Activation of STAT3 by cadherin engagement3JAK1, JAK2, TYK2
RAF-independent MAPK1/3 activation2JAK1, JAK2
Interleukin-7 signaling2JAK1, JAK3
Interleukin-12 family signaling2JAK1, JAK2

Dominant GO biological processes

GO termTargets
protein phosphorylation4
cell surface receptor signaling pathway via JAK-STAT4
cytokine-mediated signaling pathway4
cell differentiation4
intracellular signal transduction4
growth hormone receptor signaling pathway via JAK-STAT4
regulation of cell-cell adhesion4
type II interferon-mediated signaling pathway3
cellular response to virus3
regulation of receptor signaling pathway via JAK-STAT3
regulation of alpha-beta T cell activation3
interleukin-15-mediated signaling pathway2
interleukin-4-mediated signaling pathway2
interleukin-2-mediated signaling pathway2
interleukin-7-mediated signaling pathway2

Indications & clinical

Indications

13 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
atopic eczema3MONDO:0004980EFO:0000274
Crohn disease3MONDO:0005011EFO:0000384
ulcerative colitis3MONDO:0005101EFO:0000729
psoriatic arthritis3MONDO:0011849EFO:0003778
ankylosing spondylitis3MONDO:0005306EFO:0003898
juvenile idiopathic arthritis3MONDO:0011429EFO:0002609
temporal arteritis3MONDO:0008538EFO:1001209
hidradenitis suppurativa3MONDO:0006559EFO:1000710
vitiligo3MONDO:0008661EFO:0004208
rheumatoid arthritis3MONDO:0008383EFO:0000685
alopecia areata3MONDO:0005340EFO:0004192
Takayasu arteritis3MONDO:0017991EFO:1001857
systemic lupus erythematosus2MONDO:0007915MONDO:0007915

Clinical trials

Total trials: 101.

Phase distribution

PhaseTrials
PHASE343
PHASE218
Not specified18
PHASE412
PHASE16
PHASE2/PHASE32
PHASE1/PHASE21
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06520397PHASE4RECRUITINGEfficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn’s Disease
NCT06687551PHASE4NOT_YET_RECRUITINGJAK Inhibitor Dose TAPering Strategy Study
NCT07258771PHASE4RECRUITINGUpadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis
NCT07352566PHASE4NOT_YET_RECRUITINGUtilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT07502339PHASE4NOT_YET_RECRUITINGUpadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis
NCT07510191PHASE4RECRUITINGTNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn’s Disease With Suboptimal Response
NCT07546097PHASE4RECRUITINGComparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）
NCT07550673PHASE4RECRUITINGUpadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）
NCT05080218PHASE4COMPLETEDCOVID-19 VaccinE Response in Rheumatology Patients
NCT05153200PHASE4UNKNOWNEarly Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.
NCT05507580PHASE4COMPLETEDA Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06773403PHASE4TERMINATEDUpadacitinib for Prurigo Nodularis
NCT02629159PHASE3ACTIVE_NOT_RECRUITINGA Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT03006068PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03345823PHASE3ACTIVE_NOT_RECRUITINGA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn’s Disease Who Completed the Studies M14-431 or M14-433
NCT03568318PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT04161898PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
NCT05609630PHASE3RECRUITINGStudy of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT05782907PHASE3ACTIVE_NOT_RECRUITINGStudy to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05814627PHASE3ACTIVE_NOT_RECRUITINGStudy to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
NCT05843643PHASE3ACTIVE_NOT_RECRUITINGProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05889182PHASE3RECRUITINGA Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT06012240PHASE3RECRUITINGA Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06118411PHASE3ACTIVE_NOT_RECRUITINGA Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06227910PHASE3RECRUITINGA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn’s Disease
NCT06332534PHASE3RECRUITINGCrohn’s Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn’s Disease
NCT06461897PHASE3RECRUITINGA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06660693PHASE3RECRUITINGComparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis
NCT06701331PHASE3ACTIVE_NOT_RECRUITINGSafety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis
NCT06928272PHASE3RECRUITINGLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study
NCT07023302PHASE3RECRUITINGA Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
NCT07149467PHASE3NOT_YET_RECRUITINGUstekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn’s Disease: A Multicenter, Randomized, Parallel-Controlled Study
NCT02675426PHASE3COMPLETEDA Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
NCT02706847PHASE3COMPLETEDA Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs
NCT02706873PHASE3COMPLETEDA Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
NCT02706951PHASE3COMPLETEDA Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)
NCT02720523PHASE2/PHASE3COMPLETEDA Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
NCT02819635PHASE2/PHASE3COMPLETEDA Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT02955212PHASE3COMPLETEDA Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
NCT03086343PHASE3COMPLETEDA Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

126 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
DEUCRAVACITINIBChEMBL + PubChemPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
PazopanibChEMBL + PubChemPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
RITLECITINIBChEMBL + PubChemPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
ABROCITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
BARICITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
FEDRATINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
FILGOTINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
MIDOSTAURINChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
MOMELOTINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
NINTEDANIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
PACRITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
PEFICITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
RUXOLITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
SUNITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
TOFACITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
BREPOCITINIBChEMBLPhase 3JAK1, JAK2, JAK3, TYK2
DELGOCITINIBChEMBLPhase 3JAK1, JAK2, JAK3, TYK2
DOVITINIBChEMBLPhase 3JAK1, JAK2, JAK3, TYK2
ITACITINIBChEMBLPhase 3JAK1, JAK2, JAK3, TYK2
LESTAURTINIBChEMBLPhase 3JAK1, JAK2, JAK3, TYK2
AT-9283ChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
ATINVICITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
AZD-1480ChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
BMS-911543ChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
CC-401ChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
CERDULATINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
DECERNOTINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
GANDOTINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
GOLIDOCITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
GUSACITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
IFIDANCITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
IZENCITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
NEZULCITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
NS-018ChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
OCLACITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
R-406ChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
ROPSACITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
SOLCITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
SU-014813ChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
TOZASERTIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
AfatinibPubChemApprovedJAK1, JAK2, JAK3, TYK2
GefitinibPubChemApprovedJAK1, JAK2, JAK3, TYK2
IdelalisibPubChemApprovedJAK1, JAK2, JAK3, TYK2
SelumetinibPubChemApprovedJAK1, JAK2, JAK3, TYK2
dacomitinibChEMBL + PubChemPhase 4 (approved)JAK1, JAK3, TYK2
IMATINIBChEMBL + PubChemPhase 4 (approved)JAK1, JAK2, TYK2
AXITINIBChEMBLPhase 4 (approved)JAK2, JAK3, TYK2
BOSUTINIBChEMBLPhase 4 (approved)JAK2, JAK3, TYK2
CERITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3
DASATINIBChEMBLPhase 4 (approved)JAK2, JAK3, TYK2
ENTRECTINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3
ERLOTINIBChEMBLPhase 4 (approved)JAK2, JAK3, TYK2
ABIVERTINIBChEMBLPhase 3JAK1, JAK2, JAK3
ALVOCIDIBChEMBLPhase 3JAK2, JAK3, TYK2
DEFACTINIBChEMBLPhase 3JAK2, JAK3, TYK2
BMS-919373ChEMBLPhase 2JAK2, JAK3, TYK2
CENISERTIBChEMBLPhase 2JAK2, JAK3, TYK2
LONDAMOCITINIBChEMBLPhase 2JAK1, JAK2, TYK2
belumosudilPubChemApprovedJAK2, JAK3, TYK2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot